Retinal illustration beside text announcing J&J’s acquisition agreement with Ollin Biosciences for $2.2 billion upfront and highlighting its Phase 3 candidate OLN324.

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324

Johnson & Johnson announced on November 16, 2026, that it had agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, an investigational antibody in Phase 3 development for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OLN324 targets the same two proteins as Roche’s Vabysmo, an approved treatment for both conditions. (Fierce Biotech’s coverage of the Ollin acquisition)

ItemDetails
AcquirerJohnson & Johnson
Target companyOllin Biosciences
Acquisition terms$2.2 billion upfront and up to approximately $1.125 billion in regulatory and commercial milestones
Lead candidateOLN324, a bispecific antibody targeting VEGF and angiopoietin-2 (Ang2)
Route of administrationIntravitreal injection
Phase 3 developmentWet age-related macular degeneration and diabetic macular edema

J&J expects the acquisition to close by the end of 2026, subject to regulatory approvals and other customary conditions. Once the acquisition closes, Blackstone Life Sciences is set to provide $750 million over multiple years under a separate agreement to fund OLN324’s Phase 3 program. Blackstone would be eligible for certain regulatory and sales milestone payments and single-digit royalties. (J&J’s acquisition and funding announcement)

What OLN324 showed against Vabysmo

The randomized Phase 1b JADE study enrolled 164 patients with wet AMD or DME. Participants received three monthly injections of OLN324 or faricimab, the active ingredient in Vabysmo. They were followed through week 20 and could receive additional injections if they met the study’s retreatment criteria. The study primarily assessed safety and tolerability. Changes in vision and retinal anatomy were exploratory measures.

The imaging results differed by disease. In DME, Ollin reported greater reductions in central retinal thickness with OLN324. In wet AMD, central retinal thickness fell by similar amounts with the two treatments, while a separate imaging measure showed a greater reduction in pigment epithelial detachment thickness with OLN324 4 mg. Among wet AMD patients, 82% of those assigned to OLN324 4 mg completed the 12 weeks after the last scheduled injection without retreatment, compared with 81% on faricimab. (Ollin’s 20-week JADE results)

In wet AMD, some patients receiving Vabysmo can already go 16 weeks between injections after their initial monthly doses and follow-up assessments. That puts the JADE findings in context. Whether OLN324 can preserve vision over longer intervals remains open after the 12-week retreatment assessment. (FDA prescribing information for Vabysmo)

The two registered Phase 3 wet AMD trials compare OLN324 with Lucentis and Eylea, respectively, and both use a change in best-corrected visual acuity as their primary endpoint. The two DME trials use Eylea as the comparator. The direct comparison with Vabysmo comes from Phase 1b. (MOJAVE Phase 3 trial record)

For me, what matters most is whether a new treatment can protect vision and make it easier for patients to keep up with care. Losing central vision can make everyday things like reading or recognizing faces harder. Repeated trips for eye injections also take time and planning, especially for people who rely on someone else to get to appointments. If OLN324 can preserve vision while allowing more time between injections, that would make a meaningful difference in daily life.

For more on how researchers are testing longer injection intervals in wet AMD, read my previous coverage of Kodiak’s Phase 3 Zenkuda results.


Comments

Leave a Reply